Deep learning use is growing in many numerical simulation fields, and drug discovery does not escape this trend. Indeed, before proceeding with in vitro and then in vivo experiments, drug discovery now relies on in silico techniques such as molecular docking to narrow the number of experiments and identify the best candidates. This method explores the receptor surface and the ligand's conformational space, providing numerous ligand-receptor poses. All these poses are then scored and ranked by a scoring function allowing to predict the best poses among all, then compare different ligands regarding a given receptor or different targets regarding a given ligand. Since the 2010s, numerous deep learning methods have been used to tackle this problem. Nowadays, there are two significant trends in deep learning for molecular docking: (i) the augmentation of available structural data and (ii) the use of a new kind of neural network: the graph convolutional neural networks (GCNs). In this paper, we propose the study of training scalability of a GCN-a molecular complex scoring function-on an increasing number of GPUs and with a variety of batch sizes. After a hyperparameter analysis, we achieve an 80% reduction in the training time, but this improvement sometimes involves a performance metrics degradation that the final users must ponder.